JMP Securities analyst Jonathan Wolleben raised the firm’s price target on Pharvaris to $50 from $49 and keeps an Outperform rating on the shares. Pharvaris has begun its Phase 3 RAPIDe-3 trial of deucrictibant for acute hereditary angioedema and will have its end-of-Phase 2 meeting with the FDA this quarter to discuss its Phase 3 CHAPTER-3 trial for HAE prophylaxis, the analyst tells investors in a research note. The firm likes that RAPIDe-3 kicked off on schedule with the final study design largely in line with expectations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris Excels in HAE Treatment Advances
- Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
- Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
- Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
